| Eye Lymphoma studied in …STUDIED_INderived72 of 72show fewer |
|---|
| → studied in | NCT07583810Phase 2 · recruiting Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 72 trials mapped (7 active) | — | — | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06973811Phase 2 · recruiting ZR-MTX for PIOL Phase II Trial · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07402876Phase 3 · recruiting A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Vitreoretinal Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07176130active not recruiting Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05841914recruiting Multicentre Implementation and Validation of a Molecular Diagnostic for VitreoRetinal Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523223Phase 1 · completed Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05950490unknown Construction of Diagnosis and Treatment System for Primary Vitreoretinal Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Vitreoretinal Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02542514Phase 2 · completed Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01805037Phase 1/Phase 2 · terminated Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04899453Phase 2 · unknown Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Vitreoretinal Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02037256NA · completed Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00536601NA · completed High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01678443Phase 1 · terminated Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01258998Phase 2 · completed Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01542918Phase 1 · completed Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089011Phase 2 · completed Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006251Phase 1/Phase 2 · completed Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00014235NA · completed Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003196NA · completed Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01326702Phase 1/Phase 2 · completed Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03746223Phase 2 · unknown Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01839916Phase 2 · completed Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01722305Phase 1 · completed Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01273766Phase 2 · completed Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01789255Phase 2 · completed Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01053494NA · completed Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02168907Phase 1 · terminated CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01129193Phase 1 · completed AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01567709Phase 1 · completed Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00867529Phase 2 · completed Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01254578Phase 1 · completed Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01419795Phase 2 · terminated Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00072514Phase 2 · completed Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00118352Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00112593NA · completed Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01110135Phase 2 · completed Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01427881Phase 2 · completed Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00049504Phase 2 · completed Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02281279Phase 1/Phase 2 · withdrawn Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01652014Phase 2 · withdrawn Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01748721Phase 1 · completed MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02109224Phase 1 · terminated Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01658319Phase 1 · completed Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959477early Phase 1 · completed Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00608361Phase 1 · completed Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00720135Phase 1 · completed Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769911NA · withdrawn Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00221325Phase 1 · completed A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01158274Phase 1 · completed RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089076Phase 1/Phase 2 · terminated MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00054639Phase 2 · completed Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00933985Phase 1 · terminated Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01231919Phase 1 · completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00890747Phase 1 · completed Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00101205Phase 1 · terminated Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00499811Phase 1 · completed Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00458731Phase 1 · completed Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00293345Phase 1 · completed 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00354185Phase 1 · terminated PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00348985Phase 1 · completed PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00004241Phase 1 · completed 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00025415Phase 1 · completed Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00089271Phase 1 · completed 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00003970Phase 1 · completed Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00077155Phase 1 · completed Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00098891Phase 1 · completed MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01116154Phase 1 · terminated Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01177371Phase 2 · completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma · condition mapped ALIAS · 72 trials mapped (7 active) | — | — | Primary Intraocular Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |